Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2017 Sep 27;16(12):2892–2901. doi: 10.1158/1535-7163.MCT-17-0170

Table 2.

Performance of gene signatures in a PDX model and triple-negative breast cancer patients

Response to Olaparib in PDX (n=7) TCGA
(n=82)

Gene signatures Acc Sens Spec PPV NPV Positive
test
Positive
Test

Combined PARP inhibitor 0.86 0.75 1.00 1.00 0.75 0.43 0.45
Olaparib (Bajrami et al.) (24) 0.71 0.50 1.00 0.50 0.60 0.29 0.49
Talazoparib (Shen et al.) (25) 0.71 0.75 0.67 0.75 0.67 0.43 0.41
HRD Deficiency (Peng et al.) (28) 0.71 0.50 1.00 0.50 0.60 0.29 0.29
Olaparib (Daemen et al.) (20) 0.57 0.25 1.00 1.00 0.50 0.14 0.48
BRCAness (Konstantinopoulos et al.) (26) 0.57 0.75 0.33 0.60 0.50 0.71 0.78
BRCA2MUT (Larsen et al.) (27) 0.43 0.50 0.33 0.50 0.33 0.57 0.68
BRCA1MUT (Larsen et al.) (27) 0.29 0.50 0.00 0.40 0.00 0.71 0.51

Abbreviations: Acc, overall accuracy; Sens, sensitivity; Spec, specificity; PPV, positive predictive value, NPV, negative predictive value.